Talk:Palbociclib
Add topic| This is the talk page for discussing improvements to the Palbociclib article. This is not a forum for general discussion of the subject of the article. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Palbociclib.
|
Need to clarify the HER2-negative
[edit]Is approval only for ER+ if patient/tumour also HER2-negative ? - Rod57 (talk) 04:22, 30 December 2015 (UTC)
What next - PALOMA-2 - EU
[edit]When is PALOMA-2 due to report data ? Is it needed for an EU application ? When is an EU application expected ? - Rod57 (talk) 18:02, 30 December 2015 (UTC)
History - Chemistry
[edit]How was this molecule found ? Is it a derivative or analogue of a natural molecule ? - Rod57 (talk) 19:17, 30 December 2015 (UTC) To partially answer your question, a sustained medicinal chemistry effort was made to identify selective Cdk4/6 inhibitors. A description of the work conducted over many years can be found in the following references: https://pubs.acs.org/doi/abs/10.1021/jm049355%2B Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4, Scott N. VanderWel, Patricia J. Harvey, Dennis J. McNamara, et al, Adapted with permission from the Journal of Medicinal Chemistry, American Chemical Society, Apr 1, 2005, Copyright © 2005, American Chemical Society. (full article is paywall protected). Additional information may be available in the references contained in the footnotes. Continued synthetic work prepared and identified PD 0332991 which would later be named Palbociclib, the Cdk4-inhibiting component in (IBRANCE®, Pfizer Inc.). Structural similarity of the earlier leads to PD 0332991 can be seen: https://pubs.acs.org/doi/10.1021/jm049354h Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6, Peter L. Toogood, Patricia J. Harvey, Joseph T. Repine, et al., Adapted with permission from the Journal of Medicinal Chemistry, American Chemical Society, Apr 1, 2005, Copyright © 2005, American Chemical Society. (full article is paywall protected).JTR26 (talk) 15:32, 21 May 2018 (UTC)
How is it administered
[edit]How is it administered (oral?, IV?, SC?). How often ? - Rod57 (talk) 17:36, 25 November 2016 (UTC)
Theory/motivation
[edit]Why is it added to other therapies ? Is it to kill cancer cells, avoid resistance, or reduce side-effects ? - Rod57 (talk) 17:40, 25 November 2016 (UTC)